MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.intimp.2024.113996

Медицинская библиотека · International immunopharmacology · 2025

Fostamatinib alleviates temporomandibular joint osteoarthritis by maintaining cartilage homeostasis through MAPK/NF-κB and AKT/mTOR pathways.

Zhang Yuxin, Zhang Dahe, Xu Qingyu, Xia Simo, Shen Pei, Yang Chi

СтатьяПеревод в очереди

Аннотация

Temporomandibular joint osteoarthritis (TMJ OA) is a common degenerative disease characterized by cartilage degeneration. However, the therapeutic strategies aimed to maintain cartilage homeostasis remain unclear. Fostamatinib (Fos) is a potential clinical drug for rheumatoid arthritis (RA) and predicted as target drug for many inflammatory diseases. In this study we investigated the therapeutic effects of Fos for TMJ OA and underlying mechanisms. Interleukin-1β (IL-1β) was used to construct a condylar chondrocyte injury model in vitro and rat TMJ OA models were induced by unilateral anterior crossbite (UAC) in vivo. Subsequently, a series of experiments were performed to assess the therapeutic effects and potential mechanisms of Fos in TMJ OA. Herein, we verified that Fos improved IL-1β-induced decrease in chondrocyte viability and proliferation, as well as inhibited cell apoptosis. Additionally, Fos could alleviate IL-1β-induced inflammation, ECM degradation, and chondrocyte phenotype change through blocking MAPK/NF-κB pathways, as well as promote chondrocyte autophagy by regulating AKT/mTOR pathways. The therapeutic effects of Fos on TMJ OA were further validated through rat UAC model in vivo. Overall, Fos could maintaining cartilage homeostasis through regulating chondrocyte inflammation, ECM degradation, and abnormal cell biological behaviors (apoptosis and autophagy), which made it a promising small molecule drug for TMJ OA early intervention.

Для цитирования: Zhang Yuxin, Zhang Dahe, Xu Qingyu, Xia Simo, Shen Pei, Yang Chi. Fostamatinib alleviates temporomandibular joint osteoarthritis by maintaining cartilage homeostasis through MAPK/NF-κB and AKT/mTOR pathways.. International immunopharmacology. 2025. DOI: 10.1016/j.intimp.2024.113996.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.